Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) registered a 4.55% increase, still its new closing price is 21.97% up from the company’s 1 year high of 2.16.It posted 11.03% gains in previous 5 sessions and is now the subject of 4 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 1 buy or better ratings. The 7 stock analysts following this company have an average price target at $4.50, with individual PT in the $3.50-$6.00 range. The shares moved at $1.61, implying that brokerage firms see shares gaining about 11.81% in twelve months time.
Arena Pharmaceuticals, Inc. (ARNA) SEC Form 4 News
The stock is getting much attention these days as insiders are offloading shares while they posted a 13.38% rise year to date. A Director at Arena Pharmaceuticals, Inc. (ARNA) offloaded shares in a transaction closed on Monday June 13, 2016. White Christine Anna sold 18,728 shares in the company at $1.99 each and collected $37,000 in proceeds. White Christine Anna now owns 85,529 shares in the company after this transaction. A Director in the company, WOODS RANDALL E, disclosed a transaction on Monday March 30, 2015 that ended up generating $342,000 from the sale of 76,268 shares at $4.49 per share.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Upcoming Results on Tap
Arena Pharmaceuticals, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.08 in that period. Sales during the quarter are predicted to arrive at $8.75 million.
Earnings surprise history: Last quarter, the company posted approximately $19.24 million in revenue and EPS of $-0.05. The mean forecast was for $13.99 million and $-0.07 a share, respectively. One quarter earlier, revenue for the stock was at $9.51 million, with earnings at $-0.09/share.
Arena Pharmaceuticals, Inc. (ARNA) Brokerage Update
Arena Pharmaceuticals, Inc. (ARNA) is in Davenport’s research list so their analyst rating change is noteworthy. These shares were downgraded to Neutral from Buy by Davenport, according to news reported on Friday September 17, 2010.Another important research note was issued by Barclays Capital on Tuesday September 14, 2010.The firm downgraded ARNA to Underweight from Equal Weight. Over the last six months and over the last three months, the shares of Arena Pharmaceuticals, Inc. (ARNA), have changed -1.23% and 8.78%, respectively.
